Drug Trial Radar · NCT02380053
Chronic Beta-blockade and Cardiopulmonary Exercise in COPD
Last checked: Nov 19, 2026Latest source record: Jun 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Planned (sponsor's estimate)
Start
Jun 7, 2016
Primary completion
Apr 30, 2019
Study completion Apr 30, 2019
Sponsor
- Lead sponsor
- University of DundeeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
What are the differential effects of beta-blockers on lung and heart function during exercise in chronic obstructive pulmonary disease (COPD)? COPD is a major cause of illness and death. Not only do these individuals suffer from lung disease, but COPD often leads to other illnesses, particularly heart disease. Beta-blockers very successfully treat heart disease. It is therefore logical that one would want to use this treatment in COPD patients with heart disease too. However, there has always been concern that beta-blockers could cause significant problems in COPD by worsening lung function, as these can have the opposite effect to inhalers used to treat COPD that open up airways. Pointedly, there is increasing evidence that despite this problem, COPD patients who have been prescribed beta-blockers have been shown to gain benefit particularly in terms of preventing death. In this study, the investigators therefore want to examine which beta-blocker might be the safest for COPD patients, as each work slightly differently. Some beta-blockers may have a more beneficial effect on airways than others, whilst still benefitting the heart. The investigators will study two different beta-blockers; one that potentially narrows airways and one that potentially opens airways. The investigators will be using cardiopulmonary exercise testing (an exercise bike that measures both heart and lung function during exercise) to look for differences between both beta-blockers primarily in terms of lung function but also with information about the heart. The investigators will recruit people with moderate to severe COPD who are able to complete a cycle exercise test through their respiratory research department. The study will last for 10-12 weeks with 5 main visits to the department for serial exercise tests, breathing tests, simple heart function tests and simple blood tests that will tell the investigators what other effects these beta-blockers are having on the heart and lungs.
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
BisoprololDrug
2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
CeliprololDrug
2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Inspiratory Capacity (IC) from rest to isotime peak.Time frame: Baseline to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asthma and Allergy Research Group, Ninewells Hospital and Medical School, University of Dundee
Dundee, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.